This Empagliflozin, Dapagliflozin and Canagliflozin market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.
The empagliflozin, dapagliflozin and canagliflozin market size has grown steadily in recent years. It will grow from $9.64 billion in 2024 to $9.94 billion in 2025 at a compound annual growth rate (CAGR) of 3.1%. The growth in the historic period can be attributed to the increase in the prevalence of type 2 diabetes globally, increased awareness about the benefits of SGLT2 inhibitors, growth in the elderly population, growth in the prevalence of obesity, and increase in focus on personalized medicine.
The empagliflozin, dapagliflozin and canagliflozin market size is expected to see steady growth in the next few years. It will grow to $11.06 billion in 2029 at a compound annual growth rate (CAGR) of 2.7%. The growth in the forecast period can be attributed to increasing demand for oral diabetes medications, increasing investments in diabetes research and drug development, increasing healthcare expenditure, rising awareness and diagnosis of pre-diabetes conditions, and increasing focus on combination therapies. Major trends in the forecast period include technological advancements, combination therapies, telehealth, health data analytics, and patient data security.
The growing prevalence of diabetes is expected to drive the expansion of the empagliflozin, dapagliflozin, and canagliflozin market. Diabetes is a chronic health condition characterized by high blood sugar levels due to insufficient insulin production or the body's inability to use insulin effectively. The rise in diabetes cases can be attributed to various factors, including sedentary lifestyles, poor dietary choices, genetic factors, urbanization, aging populations, limited healthcare access, and increasing obesity rates globally. Empagliflozin, dapagliflozin, and canagliflozin are used to manage diabetes by lowering blood sugar levels through the inhibition of sodium-glucose co-transporter-2 (SGLT2) in the kidneys, facilitating glucose excretion via urine. For example, in June 2024, the National Health Service (NHS) reported a sharp increase in diabetes cases among individuals under 40, rising from 173,166 in 2022 to 216,440 in 2023. This rapid rise underscores a concerning trend in the younger population. As a result, the growing prevalence of diabetes is fueling the market growth for empagliflozin, dapagliflozin, and canagliflozin.
Key players in the empagliflozin, dapagliflozin, and canagliflozin markets are concentrating on creating innovative products, such as treatments for pediatric type-2 diabetes, to cater to a wider patient base and enhance their market presence. Pediatric type-2 diabetes treatment involves managing blood sugar through lifestyle modifications, medications, and occasionally insulin therapy specifically designed for children and adolescents. For instance, in June 2024, AstraZeneca, a UK-based pharmaceutical company, received approval from the US Food and Drug Administration (FDA) for Farxiga (dapagliflozin) to improve glycemic control in pediatric patients aged 10 and older with type 2 diabetes. This approval followed positive results from the T2NOW Phase III clinical trial, one of the largest pediatric type-2 diabetes studies, demonstrating that Farxiga significantly reduced HbA1c levels compared to a placebo. The safety profile of Farxiga in this age group was consistent with its profile in adults with type 2 diabetes. This milestone is significant as oral treatment options for pediatric type-2 diabetes have been scarce, highlighting AstraZeneca's dedication to advancing treatments for cardiovascular, renal, and metabolic diseases.
In March 2024, Nirma Limited, an India-based company in the chemical industry specializing in manufacturing, retailing, and distributing commercial and industrial cleaning products, acquired a 75% stake in Glenmark Life Sciences for $682 million, the amount undisclosed. Through this acquisition, Nirma Limited aims to strengthen its foothold in the pharmaceutical sector, diversify its product portfolio, and leverage research and development capabilities to drive sustainable long-term growth. Glenmark Life Sciences, an India-based pharmaceutical company, manufactures active pharmaceutical ingredients (APIs) for empagliflozin, dapagliflozin, and canagliflozin, which are used in diabetes treatment production.
Major companies operating in the empagliflozin, dapagliflozin and canagliflozin market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline plc, Eli Lilly and Company, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., MSN Laboratories Private Limited, Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Cadila Healthcare Limited, Apotex Inc., Lupin Limited, Biocon Limited, Alkem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd.
North America was the largest region in the empagliflozin, dapagliflozin and canagliflozin market in 2024. The regions covered in the empagliflozin, dapagliflozin and canagliflozin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the empagliflozin, dapagliflozin and canagliflozin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Empagliflozin, dapagliflozin, and canagliflozin are medications known as sodium-glucose co-transporter-2 (SGLT-2) inhibitors, primarily prescribed for managing type 2 diabetes mellitus. These oral medications are part of a comprehensive diabetes treatment plan that also involves diet, exercise, and potentially other medications.
The specific types of these SGLT-2 inhibitors include empagliflozin, dapagliflozin, and canagliflozin. Empagliflozin is used mainly to reduce blood sugar levels in adults with type 2 diabetes by aiding the kidneys in expelling glucose through urine. These medications are available in various applications, including application I, application II, application III, and application IV, and can be purchased through hospitals and pharmacies.
The empagliflozin, dapagliflozin and canagliflozin market research report is one of a series of new reports that provides empagliflozin, dapagliflozin and canagliflozin market statistics, including empagliflozin, dapagliflozin and canagliflozin industry global market size, regional shares, competitors with an empagliflozin, dapagliflozin and canagliflozin market share, detailed empagliflozin, dapagliflozin and canagliflozin market segments, market trends, and opportunities, and any further data you may need to thrive in the empagliflozin, dapagliflozin and canagliflozin industry. This empagliflozin, dapagliflozin and canagliflozin research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The empagliflozin, dapagliflozin and canagliflozin market consists of sales of jardiance, glyxambi, synjardy, farxiga, and invokamet. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The empagliflozin, dapagliflozin and canagliflozin market size has grown steadily in recent years. It will grow from $9.64 billion in 2024 to $9.94 billion in 2025 at a compound annual growth rate (CAGR) of 3.1%. The growth in the historic period can be attributed to the increase in the prevalence of type 2 diabetes globally, increased awareness about the benefits of SGLT2 inhibitors, growth in the elderly population, growth in the prevalence of obesity, and increase in focus on personalized medicine.
The empagliflozin, dapagliflozin and canagliflozin market size is expected to see steady growth in the next few years. It will grow to $11.06 billion in 2029 at a compound annual growth rate (CAGR) of 2.7%. The growth in the forecast period can be attributed to increasing demand for oral diabetes medications, increasing investments in diabetes research and drug development, increasing healthcare expenditure, rising awareness and diagnosis of pre-diabetes conditions, and increasing focus on combination therapies. Major trends in the forecast period include technological advancements, combination therapies, telehealth, health data analytics, and patient data security.
The growing prevalence of diabetes is expected to drive the expansion of the empagliflozin, dapagliflozin, and canagliflozin market. Diabetes is a chronic health condition characterized by high blood sugar levels due to insufficient insulin production or the body's inability to use insulin effectively. The rise in diabetes cases can be attributed to various factors, including sedentary lifestyles, poor dietary choices, genetic factors, urbanization, aging populations, limited healthcare access, and increasing obesity rates globally. Empagliflozin, dapagliflozin, and canagliflozin are used to manage diabetes by lowering blood sugar levels through the inhibition of sodium-glucose co-transporter-2 (SGLT2) in the kidneys, facilitating glucose excretion via urine. For example, in June 2024, the National Health Service (NHS) reported a sharp increase in diabetes cases among individuals under 40, rising from 173,166 in 2022 to 216,440 in 2023. This rapid rise underscores a concerning trend in the younger population. As a result, the growing prevalence of diabetes is fueling the market growth for empagliflozin, dapagliflozin, and canagliflozin.
Key players in the empagliflozin, dapagliflozin, and canagliflozin markets are concentrating on creating innovative products, such as treatments for pediatric type-2 diabetes, to cater to a wider patient base and enhance their market presence. Pediatric type-2 diabetes treatment involves managing blood sugar through lifestyle modifications, medications, and occasionally insulin therapy specifically designed for children and adolescents. For instance, in June 2024, AstraZeneca, a UK-based pharmaceutical company, received approval from the US Food and Drug Administration (FDA) for Farxiga (dapagliflozin) to improve glycemic control in pediatric patients aged 10 and older with type 2 diabetes. This approval followed positive results from the T2NOW Phase III clinical trial, one of the largest pediatric type-2 diabetes studies, demonstrating that Farxiga significantly reduced HbA1c levels compared to a placebo. The safety profile of Farxiga in this age group was consistent with its profile in adults with type 2 diabetes. This milestone is significant as oral treatment options for pediatric type-2 diabetes have been scarce, highlighting AstraZeneca's dedication to advancing treatments for cardiovascular, renal, and metabolic diseases.
In March 2024, Nirma Limited, an India-based company in the chemical industry specializing in manufacturing, retailing, and distributing commercial and industrial cleaning products, acquired a 75% stake in Glenmark Life Sciences for $682 million, the amount undisclosed. Through this acquisition, Nirma Limited aims to strengthen its foothold in the pharmaceutical sector, diversify its product portfolio, and leverage research and development capabilities to drive sustainable long-term growth. Glenmark Life Sciences, an India-based pharmaceutical company, manufactures active pharmaceutical ingredients (APIs) for empagliflozin, dapagliflozin, and canagliflozin, which are used in diabetes treatment production.
Major companies operating in the empagliflozin, dapagliflozin and canagliflozin market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline plc, Eli Lilly and Company, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., MSN Laboratories Private Limited, Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Cadila Healthcare Limited, Apotex Inc., Lupin Limited, Biocon Limited, Alkem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd.
North America was the largest region in the empagliflozin, dapagliflozin and canagliflozin market in 2024. The regions covered in the empagliflozin, dapagliflozin and canagliflozin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the empagliflozin, dapagliflozin and canagliflozin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Empagliflozin, dapagliflozin, and canagliflozin are medications known as sodium-glucose co-transporter-2 (SGLT-2) inhibitors, primarily prescribed for managing type 2 diabetes mellitus. These oral medications are part of a comprehensive diabetes treatment plan that also involves diet, exercise, and potentially other medications.
The specific types of these SGLT-2 inhibitors include empagliflozin, dapagliflozin, and canagliflozin. Empagliflozin is used mainly to reduce blood sugar levels in adults with type 2 diabetes by aiding the kidneys in expelling glucose through urine. These medications are available in various applications, including application I, application II, application III, and application IV, and can be purchased through hospitals and pharmacies.
The empagliflozin, dapagliflozin and canagliflozin market research report is one of a series of new reports that provides empagliflozin, dapagliflozin and canagliflozin market statistics, including empagliflozin, dapagliflozin and canagliflozin industry global market size, regional shares, competitors with an empagliflozin, dapagliflozin and canagliflozin market share, detailed empagliflozin, dapagliflozin and canagliflozin market segments, market trends, and opportunities, and any further data you may need to thrive in the empagliflozin, dapagliflozin and canagliflozin industry. This empagliflozin, dapagliflozin and canagliflozin research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The empagliflozin, dapagliflozin and canagliflozin market consists of sales of jardiance, glyxambi, synjardy, farxiga, and invokamet. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Empagliflozin, Dapagliflozin and Canagliflozin Market Characteristics3. Empagliflozin, Dapagliflozin and Canagliflozin Market Trends and Strategies4. Empagliflozin, Dapagliflozin and Canagliflozin Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market10 Mg25 Mg5 Mg100 Mg300 Mg32. Global Empagliflozin, Dapagliflozin and Canagliflozin Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Empagliflozin, Dapagliflozin and Canagliflozin Market34. Recent Developments in the Empagliflozin, Dapagliflozin and Canagliflozin Market
5. Global Empagliflozin, Dapagliflozin and Canagliflozin Growth Analysis and Strategic Analysis Framework
6. Empagliflozin, Dapagliflozin and Canagliflozin Market Segmentation
50 Mg
10 Mg
7. Empagliflozin, Dapagliflozin and Canagliflozin Market Regional and Country Analysis
8. Asia-Pacific Empagliflozin, Dapagliflozin and Canagliflozin Market
9. China Empagliflozin, Dapagliflozin and Canagliflozin Market
10. India Empagliflozin, Dapagliflozin and Canagliflozin Market
11. Japan Empagliflozin, Dapagliflozin and Canagliflozin Market
12. Australia Empagliflozin, Dapagliflozin and Canagliflozin Market
13. Indonesia Empagliflozin, Dapagliflozin and Canagliflozin Market
14. South Korea Empagliflozin, Dapagliflozin and Canagliflozin Market
15. Western Europe Empagliflozin, Dapagliflozin and Canagliflozin Market
16. UK Empagliflozin, Dapagliflozin and Canagliflozin Market
17. Germany Empagliflozin, Dapagliflozin and Canagliflozin Market
18. France Empagliflozin, Dapagliflozin and Canagliflozin Market
19. Italy Empagliflozin, Dapagliflozin and Canagliflozin Market
20. Spain Empagliflozin, Dapagliflozin and Canagliflozin Market
21. Eastern Europe Empagliflozin, Dapagliflozin and Canagliflozin Market
22. Russia Empagliflozin, Dapagliflozin and Canagliflozin Market
23. North America Empagliflozin, Dapagliflozin and Canagliflozin Market
24. USA Empagliflozin, Dapagliflozin and Canagliflozin Market
25. Canada Empagliflozin, Dapagliflozin and Canagliflozin Market
26. South America Empagliflozin, Dapagliflozin and Canagliflozin Market
27. Brazil Empagliflozin, Dapagliflozin and Canagliflozin Market
28. Middle East Empagliflozin, Dapagliflozin and Canagliflozin Market
29. Africa Empagliflozin, Dapagliflozin and Canagliflozin Market
30. Empagliflozin, Dapagliflozin and Canagliflozin Market Competitive Landscape and Company Profiles
31. Empagliflozin, Dapagliflozin and Canagliflozin Market Other Major and Innovative Companies
35. Empagliflozin, Dapagliflozin and Canagliflozin Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Empagliflozin, Dapagliflozin and Canagliflozin Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on empagliflozin, dapagliflozin and canagliflozin market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for empagliflozin, dapagliflozin and canagliflozin ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The empagliflozin, dapagliflozin and canagliflozin market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include: the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Type: Empagliflozin; Dapagliflozin; Canagliflozin2) By Application: Application I; Application II; Application III; Application IV
3) By Channel: Hospital; Pharmacy
Subsegments:
1) Empagliflozin: 10 Mg; 25 Mg; 50 Mg2) Dapagliflozin: 5 Mg; 10 Mg
3) Canagliflozin: 100 Mg; 300 Mg
Key Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; Sanofi S.a.; Bristol-Myers Squibb Company; AstraZeneca PLC
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
The major companies featured in this Empagliflozin, Dapagliflozin and Canagliflozin market report include:- Pfizer Inc.
- Merck & Co. Inc.
- Sanofi S.A.
- Bristol-Myers Squibb Company
- AstraZeneca PLC
- GlaxoSmithKline plc
- Eli Lilly and Company
- Boehringer Ingelheim GmbH
- Teva Pharmaceutical Industries Ltd.
- Astellas Pharma Inc.
- MSN Laboratories Private Limited
- Dr. Reddy's Laboratories Ltd.
- Aurobindo Pharma Limited
- Cipla Limited
- Cadila Healthcare Limited
- Apotex Inc.
- Lupin Limited
- Biocon Limited
- Alkem Laboratories Ltd.
- Torrent Pharmaceuticals Ltd.
- Alembic Pharmaceuticals Ltd.
- Intas Pharmaceuticals Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | April 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 9.94 Billion |
| Forecasted Market Value ( USD | $ 11.06 Billion |
| Compound Annual Growth Rate | 2.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 22 |
